Website
News25/Ratings9
News · 26 weeks46-14%
2025-10-262026-04-19
Mix2590d
- Insider13(52%)
- SEC Filings5(20%)
- Other4(16%)
- Earnings3(12%)
Latest news
25 items- PRFulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual MeetingFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)", clinical trial identifier, NCT06332092. This is a Phase 2 study designed to evaluate the efficacy o
- PRFulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a
- INSIDERAmendment: SEC Form 4 filed by Hsieh Ming4/A - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
- SECSEC Form DEFA14A filed by Fulgent Genetics Inc.DEFA14A - Fulgent Genetics, Inc. (0001674930) (Filer)
- SECSEC Form DEF 14A filed by Fulgent Genetics Inc.DEF 14A - Fulgent Genetics, Inc. (0001674930) (Filer)
- SECFulgent Genetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- PRFulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDxFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and acquired StrataDx for a total combined purchase price of approximately $56.9 million in cash, subject to certain post-closing adjustments. For additional information, please refer to the Form 8-K that was filed with the SEC and is av
- INSIDERSEC Form 4 filed by Chief Executive Officer Hsieh Ming4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian covered exercise/tax liability with 10,366 shares, decreasing direct ownership by 3% to 375,313 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 10,648 shares, decreasing direct ownership by 3% to 368,547 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin covered exercise/tax liability with 8,325 shares, decreasing direct ownership by 0.83% to 994,652 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 20,515 shares, decreasing direct ownership by 2% to 900,634 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECSEC Form 10-K filed by Fulgent Genetics Inc.10-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- SECFulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- PRFulgent Reports Fourth Quarter and Full Year 2025 Financial ResultsRevenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announce
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 27,453 shares and was granted 78,502 shares, increasing direct ownership by 16% to 379,195 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian covered exercise/tax liability with 26,823 shares and was granted 80,464 shares, increasing direct ownership by 16% to 385,679 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin was granted 67,120 shares and covered exercise/tax liability with 15,702 shares, increasing direct ownership by 5% to 1,002,977 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 65,511 shares and was granted 187,439 shares, increasing direct ownership by 15% to 921,149 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- PRFulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About F
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
- INSIDERChief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,331 shares, decreasing direct ownership by 0.14% to 951,559 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian covered exercise/tax liability with 4,711 shares, decreasing direct ownership by 1% to 332,038 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 3,004 shares, decreasing direct ownership by 0.91% to 328,146 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)